Log in

Relevant bibliographies by topics / Pramlintide / Journal articles

To see the other types of publications on this topic, follow the link: Pramlintide.

Journal articles on the topic 'Pramlintide'

Author: Grafiati

Published: 4 June 2021

Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pramlintide.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Pramlintide." BioDrugs 17, no. 1 (2003): 73–79. http://dx.doi.org/10.2165/00063030-200317010-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Pramlintide." Drugs in R & D 2, no. 2 (1999): 118–22. http://dx.doi.org/10.2165/00126839-199902020-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Brusegan, Adriana, Gerry McKay, and Andrea Llano. "Pramlintide." Practical Diabetes 37, no. 5 (2020): 194–95. http://dx.doi.org/10.1002/pdi.2300.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Samsom, Melvin, Lawrence A. Szarka, Michael Camilleri, Adrian Vella, Alan R. Zinsmeister, and Robert A. Rizza. "Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition." American Journal of Physiology-Gastrointestinal and Liver Physiology 278, no. 6 (2000): G946—G951. http://dx.doi.org/10.1152/ajpgi.2000.278.6.g946.

Full text

Abstract:

The amylin analog pramlintide delays gastric emptying in type I diabetics. The effects of multiple doses of pramlintide and the mechanism of action in non-amylin-deficient humans are unknown. We investigated the effects of pramlintide on gastrointestinal and colonic transit and on the plasma pancreatic polypeptide response to the meal in a parallel-group dose-response study with subjects randomized to placebo, or 30 or 60 μg (tid, sc) of pramlintide. Pramlintide delayed gastric emptying [half-time ( t½): 112 min (SE 8.7 min), 169 min (SE 12 min), or 177 min (SE 25 min) after placebo or 30- or

APA, Harvard, Vancouver, ISO, and other styles

5

Aronne, Louis, Ken Fujioka, Vanita Aroda, et al. "Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study." Journal of Clinical Endocrinology & Metabolism 92, no. 8 (2007): 2977–83. http://dx.doi.org/10.1210/jc.2006-2003.

Full text

Abstract:

Abstract Context: In previous 1-yr trials, treatment with pramlintide (120 μg), an analog of the β-cell hormone amylin, induced sustained reductions in A1C and body weight in insulin-using subjects with type 2 diabetes. Objective: To assess the potential of pramlintide as an antiobesity agent, we assessed the weight effect, safety, and tolerability of pramlintide in non-insulin-treated obese subjects with and without type 2 diabetes at doses greater than previously studied. Design/Setting: We performed a randomized, double-blind, placebo-controlled, multicenter study. Patients: A total of 204

APA, Harvard, Vancouver, ISO, and other styles

6

McQueen, Joanna. "Pramlintide acetate." American Journal of Health-System Pharmacy 62, no. 22 (2005): 2363–72. http://dx.doi.org/10.2146/ajhp050341.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Cada, Dennis J., Terri Levien, and Danial E. Baker. "Pramlintide Acetate." Hospital Pharmacy 40, no. 7 (2005): 599–613. http://dx.doi.org/10.1177/001857870504000709.

Full text

Abstract:

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized t

APA, Harvard, Vancouver, ISO, and other styles

8

Norman, P., X. Rabasseda, and P. A. Leeson. "Pramlintide Acetate." Drugs of the Future 26, no. 5 (2001): 444. http://dx.doi.org/10.1358/dof.2001.026.05.619841.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Messer, Caroline, and Dina Green. "A Review of Pramlintide in the Management of Diabetes." Clinical Medicine. Therapeutics 1 (January 2009): CMT.S2369. http://dx.doi.org/10.4137/cmt.s2369.

Full text

Abstract:

Tight glycemic control in type 1 and type 2 diabetes reduces the risk for microvascular complications, including retinopathy, nephropathy, and neuropathy. Yet, despite intensive insulin regimens, many insulin-dependent patients are unable to achieve euglycemic states. This review will focus on pramlintide, an equipotent amylin analog, and its role in the management of diabetes. Pramlintide lowers glucose through the same mechanisms as amylin: it slows gastric emptying, suppresses the postprandial rise of glucagon in patients with diabetes, and promotes satiety. Long-term clinical trials have s

APA, Harvard, Vancouver, ISO, and other styles

10

Wu, Xinghuo, Yu Song, Suyun Li, et al. "Pramlintide regulation of extracellular matrix (ECM) and apoptosis through mitochondrial-dependent pathways in human nucleus pulposus cells." International Journal of Immunopathology and Pharmacology 31 (December 19, 2017): 039463201774750. http://dx.doi.org/10.1177/0394632017747500.

Full text

Abstract:

Pramlintide, an approved analog of amylin, is responsible for regulating the physiology of energy homeostasis. The goals of this study were to investigate the roles of pramlintide in the regulation of cell survival and matrix metabolism, and further explore their underlying mechanisms, in human nucleus pulposus (NP) cells. NP cells were treated with different concentrations of pramlintide in normoxic or hypoxic conditions. Cell viability, LAC concentration, calcium concentration, mitochondrial membrane potential (ΔΨm), MMPs proteins, and apoptotic related proteins were detected. The results in

APA, Harvard, Vancouver, ISO, and other styles

11

Want, Laura. "Use of Pramlintide." Diabetes Educator 32, no. 3_suppl (2006): 111S—118S. http://dx.doi.org/10.1177/0145721706288s249.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Meade, Lisa T. "Practical Use of Exenatide and Pramlintide for the Treatment of Type 2 Diabetes." Journal of Pharmacy Practice 22, no. 6 (2009): 540–45. http://dx.doi.org/10.1177/0897190009333164.

Full text

Abstract:

Type 2 diabetes is a progressive disease that affects more than 20.8 million Americans. Traditional antihyperglycemic therapy can cause weight gain and hypoglycemia in this population. Research shows that type 2 diabetic patients have low levels of glucagon-like peptide-1 and amylin. This discovery led to the creation of 2 newer agents, exenatide and pramlintide. Exenatide, a glucagon-like peptide-1 agonist, stimulates insulin secretion, suppresses glucagon secretion, and slows gastric motility. Transient nausea is the most common side effect, which can be minimized with slow titration. Weight

APA, Harvard, Vancouver, ISO, and other styles

13

Kleppinger, Erika L., and Eva M. Vivian. "Pramlintide for the Treatment of Diabetes Mellitus." Annals of Pharmacotherapy 37, no. 7-8 (2003): 1082–89. http://dx.doi.org/10.1345/aph.1c387.

Full text

Abstract:

OBJECTIVE: To provide an overview of the role of amylin, as well as that of pramlintide, a synthetic analog of amylin, in maintaining glucose homeostasis; and discuss the pharmacology, pharmacokinetics, efficacy, adverse effects, and role of pramlintide in the control of postprandial hyperglycemia. DATA SOURCES: The data presented in this review were obtained from published literature, abstracts presented at scientific meetings, and information on file with the manufacturer. MEDLINE searches (1986–March 2003) using the search terms pramlintide and amylin were conducted to identify clinical tri

APA, Harvard, Vancouver, ISO, and other styles

14

Smith, Steven R., John E. Blundell, Colleen Burns, et al. "Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study." American Journal of Physiology-Endocrinology and Metabolism 293, no. 2 (2007): E620—E627. http://dx.doi.org/10.1152/ajpendo.00217.2007.

Full text

Abstract:

Evidence from rodent studies indicates that the β-cell-derived neurohormone amylin exerts multiple effects on eating behavior, including reductions in meal size, intake of highly palatable foods, and stress-induced sucrose consumption. To assess the effect of amylin agonism on human eating behavior we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effects of the amylin analog pramlintide on body weight, 24-h caloric intake, portion sizes, “fast food” intake, and perceived control of eating in 88 obese subjects. After a 2-day placebo lead-in, subjects s

APA, Harvard, Vancouver, ISO, and other styles

15

Salamone, Frank, and Brian A. Berelowitz. "REDUCTION IN SUBCUTANEOUS INSULIN REQUIREMENTS IN TETRAPLEGIC TYPE 1 DIABETIC WITH CERVICAL SPINAL CORD INJURY FOLLOWING PRAMLINTIDE TREATMENT." AACE Clinical Case Reports 6, no. 3 (2020): e132-e134. http://dx.doi.org/10.4158/accr-2019-0461.

Full text

Abstract:

Objective: To report a massive increase in subcutaneous insulin requirements following spinal cord injury in a type 1 diabetic and how it was managed over a 22-month period with pramlintide. Methods: A case report and brief literature review is presented. Results: The patient is a 43-year-old male who was diagnosed with type 1 diabetes mellitus at age 18. He remained relatively well-controlled without end-organ complications until age 37, when he developed a spinal epidural abscess following a methicillin-resistant Staphylococcus aureus cellulitis of the foot. The patient became ventilator-dep

APA, Harvard, Vancouver, ISO, and other styles

16

Alrefai, H. A., K. A. Latif, L. B. Hieronymus, C. R. Weakley, and R. J. Moss. "Pramlintide: Clinical Strategies for Success." Diabetes Spectrum 23, no. 2 (2010): 124–30. http://dx.doi.org/10.2337/diaspect.23.2.124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Kowalczyk, Renata, Margaret A. Brimble, Yusuke Tomabechi, Antony J. Fairbanks, Madeleine Fletcher, and Debbie L. Hay. "Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure–activity relationships for amylin receptor agonism." Org. Biomol. Chem. 12, no. 41 (2014): 8142–51. http://dx.doi.org/10.1039/c4ob01208a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Edelman, Steven Victor, Valentina Conoscenti, M. Khaled Junaidi, Nicole Close, David Sequeira, and Anh Nguyen. "A Phase 2 Evaluation of a Novel Co-Formulation of Pramlintide and Regular Insulin to Improve Postprandial Glycemic Control in Adults with Type 1 Diabetes (T1D)." Journal of the Endocrine Society 5, Supplement_1 (2021): A327—A328. http://dx.doi.org/10.1210/jendso/bvab048.669.

Full text

Abstract:

Abstract Objective: Pramlintide co-administration, used in conjunction with prandial insulin, has substantial clinical benefits to improve post-prandial glucose excursions, glycemic variability (GV) and time in range (TIR), but is associated with an increased injection burden that adversely affects adherence and persistence. A novel, fixed-ratio co-formulation of pramlintide and regular insulin (XP-3924) was evaluated in a phase 2 single injection study measuring XP-3924 pharmacokinetics (PK), glucose pharmacodynamics (PD), and its effects upon overall glycemic control. Methods: This was a Pha

APA, Harvard, Vancouver, ISO, and other styles

19

Yule, Lauren R., Rebekah L. Bower, Harveen Kaur, Renata Kowalczyk, Debbie L. Hay, and Margaret A. Brimble. "Synthesis and amylin receptor activity of glycomimetics of pramlintide using click chemistry." Organic & Biomolecular Chemistry 14, no. 23 (2016): 5238–45. http://dx.doi.org/10.1039/c6ob00850j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Hinshaw, Ling, Michele Schiavon, Ashwini Mallad та ін. "Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function". American Journal of Physiology-Endocrinology and Metabolism 307, № 6 (2014): E494—E502. http://dx.doi.org/10.1152/ajpendo.00199.2014.

Full text

Abstract:

Controlling meal-related glucose excursions continues to be a therapeutic challenge in diabetes mellitus. Mechanistic reasons for this need to be understood better to develop appropriate therapies. To investigate delayed gastric emptying effects on postprandial glucose turnover, insulin sensitivity, and β-cell responsivity and function, as a feasibility study prior to studying patients with type 1 diabetes, we used the triple tracer technique C-peptide and oral minimal model approach in healthy subjects. A single dose of 30 μg of pramlintide administered at the start of a mixed meal was used t

APA, Harvard, Vancouver, ISO, and other styles

21

Lebovitz, Harold E. "Pramlintide: profile of an amylin analog." Expert Review of Endocrinology & Metabolism 7, no. 6 (2012): 599–609. http://dx.doi.org/10.1586/eem.12.50.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Pramlintide promising in patients with NIDDM." Inpharma Weekly &NA;, no. 1098 (1997): 10. http://dx.doi.org/10.2165/00128413-199710980-00013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Pramlintide promotes weight loss in obesity." Inpharma Weekly &NA;, no. 1605 (2007): 15. http://dx.doi.org/10.2165/00128413-200716050-00040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Pramlintide improves insulin therapy in IDDM." Inpharma Weekly &NA;, no. 1086 (1997): 8. http://dx.doi.org/10.2165/00128413-199710860-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Kenley, Richard A., Fred Bancroft, James L'Italien, Anna Stepanenko, Michael Townsend, and Trupti Dixit. "Pramlintide injection drug product robustness studies." AAPS PharmSciTech 1, no. 2 (2000): 8–13. http://dx.doi.org/10.1208/pt010208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Fennoy, Ilene. "Pramlintide in Pediatric Type 1 Diabetes." Journal of Pediatrics 155, no. 3 (2009): 308–9. http://dx.doi.org/10.1016/j.jpeds.2009.04.065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

EDELMAN, S. V., T. DARSOW, and J. P. FRIAS. "Pramlintide in the treatment of diabetes." International Journal of Clinical Practice 60, no. 12 (2006): 1647–53. http://dx.doi.org/10.1111/j.1742-1241.2006.01187.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Want, L. "Use of Pramlintide: The Patient's Perspective." Diabetes Educator 32, Supplement 3 (2006): 111S—118S. http://dx.doi.org/10.1177/0145721706288249.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Traina, Andrea N., and Michael P. Kane. "Primer on Pramlintide, an Amylin Analog." Diabetes Educator 37, no. 3 (2011): 426–31. http://dx.doi.org/10.1177/0145721711403011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

da Silva, Dayana Cabral, Giselle N. Fontes, Luiza C. S. Erthal, and Luís Maurício T. R. Lima. "Amyloidogenesis of the amylin analogue pramlintide." Biophysical Chemistry 219 (December 2016): 1–8. http://dx.doi.org/10.1016/j.bpc.2016.09.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Frigori, Rafael B. "Be positive: optimizing pramlintide from microcanonical analysis of amylin isoforms." Physical Chemistry Chemical Physics 19, no. 37 (2017): 25617–33. http://dx.doi.org/10.1039/c7cp04074a.

Full text

Abstract:

Microcanonical thermostatistics analysis of multicanonical simulations of wild-type amylin isoforms is employed to screen (charged) mutations able to optimize the solubility and fibrillization-inhibitory features of pramlintide.

APA, Harvard, Vancouver, ISO, and other styles

32

Hiles, Richard A., Roger E. Bawdon, and Ezio M. Petrella. "Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)." Human & Experimental Toxicology 22, no. 12 (2003): 623–28. http://dx.doi.org/10.1191/0960327103ht402oa.

Full text

Abstract:

Two peptides, pramlintide (37 amino acids), an analog of human amylin, and exenatide, synthetic exendin-4 (39 amino acids), are both in late-stage clinical development as potential new treatments for people with diabetes. Both are potential long-term treatments, and there is the likelihood that some women will become pregnant while using one of these peptide therapies. Therefore, it was important to evaluate the potential for each peptide to cross the placental barrier and thereby result in exposure to the fetus. This was examined using ex vivo perfusions of human placentas. The fetal and mate

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Battle of the bulge: pramlintide weighs in." Inpharma Weekly &NA;, no. 1659 (2008): 16. http://dx.doi.org/10.2165/00128413-200816590-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Pramlintide improves metabolic control in diabetes mellitus." Inpharma Weekly &NA;, no. 1101 (1997): 9. http://dx.doi.org/10.2165/00128413-199711010-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

BOSCHERT, SHERRY. "Pramlintide Equals Meal Insulin, Curbs Side Effects." Family Practice News 38, no. 14 (2008): 16. http://dx.doi.org/10.1016/s0300-7073(08)70875-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Dunican, Kaelen C., Nicole M. Adams, and Alicia R. Desilets. "The Role of Pramlintide for Weight Loss." Annals of Pharmacotherapy 44, no. 3 (2010): 538–45. http://dx.doi.org/10.1345/aph.1m210.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Want, L. L., and R. Ratner. "Exenatide and pramlintide: new therapies for diabetes." International Journal of Clinical Practice 60, no. 12 (2006): 1522–23. http://dx.doi.org/10.1111/j.1742-1241.2006.01219.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Weyer, Christian, Mark S. Fineman, Susan Strobel, et al. "Properties of pramlintide and insulin upon mixing." American Journal of Health-System Pharmacy 62, no. 8 (2005): 816–22. http://dx.doi.org/10.1093/ajhp/62.8.816.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Edelman, Steve, Holly Maier, and Ken Wilhelm. "Pramlintide in the Treatment of Diabetes Mellitus." BioDrugs 22, no. 6 (2008): 375–86. http://dx.doi.org/10.2165/0063030-200822060-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Charles, M. Arthur. "Is Pramlintide an Adjunct to Insulin Therapy?" Diabetes Technology & Therapeutics 4, no. 2 (2002): 190–92. http://dx.doi.org/10.1089/15209150260007408.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Chu, Neelima V., and Steven V. Edelman. "Pramlintide as an adjunct to insulin therapy." Current Diabetes Reports 3, no. 1 (2003): 35–36. http://dx.doi.org/10.1007/s11892-003-0050-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Want, Laura L., and Robert E. Ratner. "Pramlintide: A new tool in diabetes management." Current Diabetes Reports 6, no. 5 (2006): 344–49. http://dx.doi.org/10.1007/s11892-006-0004-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Hinshaw, Ling, Michele Schiavon, Vikash Dadlani, et al. "Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes." Journal of Clinical Endocrinology & Metabolism 101, no. 5 (2016): 1954–62. http://dx.doi.org/10.1210/jc.2015-3952.

Full text

Abstract:

Abstract Context: Early postprandial hyperglycemia and delayed hypoglycemia remain major problems in current management of type 1 diabetes (T1D). Objective: Our objective was to investigate the effects of pramlintide, known to suppress glucagon and delay gastric emptying, on postprandial glucose fluxes in T1D. Design: This was a single-center, inpatient, randomized, crossover study. Patients: Twelve patients with T1D who completed the study were analyzed. Interventions: Subjects were studied on two occasions with or without pramlintide. Triple tracer mixed-meal method and oral minimal model we

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Pramlintide: beneficial adjuvant therapy for type 1 diabetes." Inpharma Weekly &NA;, no. 1371/1372 (2003): 9. http://dx.doi.org/10.2165/00128413-200313710-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Pramlintide improves glycaemic control in type 2 diabetes." Inpharma Weekly &NA;, no. 1382 (2003): 9. http://dx.doi.org/10.2165/00128413-200313820-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Childs, B. P., N. C. Kesty, E. Klein, R. Rubin, and A. Wick. "Considering Pramlintide Therapy for Postprandial Blood Glucose Control." Diabetes Spectrum 20, no. 2 (2007): 108–14. http://dx.doi.org/10.2337/diaspect.20.2.108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Vine, W., P. Smith, R. LaChappell, E. Blase, R. Lumpkin, and A. Young. "Nephrectomy Decreases Amylin and Pramlintide Clearance in Rats." Hormone and Metabolic Research 30, no. 08 (1998): 514–17. http://dx.doi.org/10.1055/s-2007-978923.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Hussar, Daniel A. "New Drugs: Exenatide, Pramlintide Acetate, and Micafungin Sodium." Journal of the American Pharmacists Association 45, no. 4 (2005): 524–27. http://dx.doi.org/10.1331/1544345054475504.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Kruger, Davida F., and Maurice A. Gloster. "Pramlintide for the Treatment of Insulin-Requiring Diabetes Mellitus." Drugs 64, no. 13 (2004): 1419–32. http://dx.doi.org/10.2165/00003495-200464130-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Adjuvant pramlintide improves glycaemic control in type 1 diabetes." Inpharma Weekly &NA;, no. 1467 (2004): 5. http://dx.doi.org/10.2165/00128413-200414670-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!